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ABSTRACT 
Objective: Anxiety disorders are the most common group of psychiatric illnesses in children. This study is to observe the effectiveness of Paroxetine 
in anxiety disorder among teenagers in South India population using Hamilton Anxiety Rating Scale (HAM-A) and to screen the possible risk for 
paroxetine in anxiety disorder among teenagers. 
Methods: This study is a prospective observational study that was conducted for a period of 6 mo. Of 84 teenage patients with anxiety disorder 
assessed using Hamilton Anxiety Rating Scale (HAM-A) were followed-up in an outpatient psychiatric ward. Study population includes both sexes, 
age group between 13 to 19 y, Teenage patient receiving paroxetine for anxiety disorder were included and patients unwilling to give written 
informed consent or assent form were excluded. 
Results: Out of 84 patients the prevalence of symptoms before the drug treatment, 65 patients were falling in very severe category, which was 
assessed by HAM-A scale. Then reassessed with drug Paroxetine at week 4 and week 8. There was a drastic reduction in the prevalence of 
symptoms in week 8 than compared to week 4. A significant reduction in body weight was also observed during the study period. Among various 
side effects, nausea was the prominent risk found during the study.  
Conclusion: The present study demonstrated that paroxetine is effective and well-tolerated for the treatment of various types of anxiety disorder in 
teenagers with few side effects. 
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INTRODUCTION 
Anxiety disorders are the most common group of psychiatric 
illnesses in children. Anxiety is a blanket term covering several 
different forms of abnormal and pathological fear. The disorder is 
frequently accompanied by physiological symptoms such as 
headache, excessive sweating, muscle spasms, palpitations, and 
hypertension, which in some cases lead to fatigue and exhaustion. 
Those affected can also flare up at times of high stress [1]. Anxiety 
disorders are the most common of mental disorders and affect more 
than 25 million Americans. But anxiety disorders are treatable and a 
number of effective treatments are available. Treatment helps most 
people lead normal productive lives [2]. According to the American 
Psychiatric Association, anxiety disorders are the most common type 
of psychiatric disorder. Despite the high prevalence rates of these 
anxiety disorders, they often are under-recognized and undertreated 
clinical problems [3]. Anxiety disorders can run in families, 
suggesting that a combination of genes and environmental stresses 
can produce disorders [4]. Selective serotonin reuptake inhibitors 
(SSRIs), serotonin-nor epinephrine reuptake inhibitors (SNRIs), and 
pregabalin are recommended as first-line drugs due to their 
favourable risk-benefit ratio, with some differentiation regarding the 
various anxiety disorders [5]. Serotonin is a chemical 
neurotransmitter that plays an important role in mood regulation, is 
one of the key factors in a lack of balance in mood disorders such as 
anxiety and depression. SSRI has serotonin reuptake reduction in 
specific neurons, causing an increase in the brain serotonin and 
reduce the symptoms of mental health disorders. SSRI, in general, 
are safer than others but have their own side effects, which are 
usually sexual, metabolic, and gastrointestinal [6]. The HAM-A was 
one of the first rating scales developed to measure the severity of 
anxiety symptoms and is still widely used today in both clinical and 
research settings. The scale consists of 14 items, each defined by a 
series of symptoms, and measures both psychic anxiety (mental 
agitation and psychological distress) and somatic anxiety (physical 
complaints related to anxiety [7]. A total of 44.9 people suffered from 
anxiety. In most of the study among gender, Women were suffered 
from various anxiety disorders compared to Men. The main objective 
of the study is to investigates the effects of paroxetine in anxiety 
disorder among teenagers in South India population using Hamilton 
Anxiety Rating Scale (HAM-A). 
MATERIALS AND METHODS 
A prospective observational study was conducted at the Outpatient 
Psychiatry ward in Sri Ramachandra medical college and Research 
Institute (SRMC and RI), Porur, Chennai, Tamilnadu for the period of 
6 mo. The study protocol was approved by the institutional Ethics 
Committee of Sri Ramachandra Institute of Higher education and 
Research, Deemed to be University, Chennai, Tamilnadu, India 
(CSP/19/Nov/81/394). After getting written informed consent or 
and assent from the patients and caretakers. The study population 
includes both sexes, age group between 13 to 19years, Teenage 
patient with an anxiety disorder and with all co-morbidities, 
Teenage patient receiving Paroxetine for anxiety disorder were 
included and Patient with other Psychiatric conditions like 
schizophrenia, Bipolar disorder, Depression, ICU’S patients, Patient 
with the previous history of hypersensitivity to SSRI and had 
serotonin syndrome, Patient with severe anxiety disorder requiring 
inpatient admission were excluded. Adverse drug reactions and its 
severity for drug paroxetine were assessed by using WHO causality 
scale. The sample size was determined by using epi software 2.1.3 
version with confidence interval 95%. The calculated sample size 
was 84. Hence with 10% of attrition rate. The sample size was found 
to be 92. The collected data were analyzed with IBM. SPSS statistic 
software version 60. To describe about the data, descriptive 
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statistics mean and standard deviation (SD) were used. To find the 
significant difference between the multivariate samples, repeated 
measures of ANOVA was used. In the above statistical tool the 
probability value 0.05 is considered as significant level. 
RESULTS 
A total of 92 teenage patients with an anxiety disorder was recruited 
as per the selection criteria and followed up during the study period. 
8 patients were lost the follow up at 12th week for various reasons 
such as, withdraw consent (5), could not be reached (1), and 
relocated (2). Finally, 84 patients completed the study and were 
assessed using Hamilton Anxiety Rating Scale (HAM-A) and weight 
was observed before and after the treatment. Out of 84 teenage 
patients, 53 were female and 31 were male. The study includes 
teenage patient’s age between 13 and 19 (18 male and 41 female). 
More number of patients found in age between 14 and 17. The study 
was assessed using HAM-A scale which includes 14 items each 
defined by a series of symptoms. Each item was rated on a 5 point 
likert response. Each item is scored on a scale of 0 (not present) to 4 
(severe), with a total score range of 0–56, where<17 indicates mild 
severity, 18–24 mild to moderate severity and 25–30 moderate to 
severe. Each question from the HAM-A scale was assessed at 
baseline (Before treatment), and at 4th and 8th week (After 
treatment) to the patients. From 84 patients 27 patients with 
generalized Anxiety disorder and Specific phobia (8 male and 11 
female respectively) were most observed in this study then 
Academic difficulty contributed as a reason for most of the anxiety 
cause in teenage patients (table 1), Followed by School dropouts (11 
patients) which also contributed second most reason for the causes 
of anxiety disorder. The Overall Anxiety score in 84 patients using 
HAM-A scale was shown in (table 2). Comparison of anxiety severity 
at Baseline (Before treatment) and week 4 and week 8(after 
treatment with paroxetine) were shown in (table 3). The prevalence 
of symptoms at baseline was very severe, then reassessed with 
paroxetine at week 4 and week 8. There was drastic reduction in the 
prevalence of symptoms in week 8 compared to week 4. The most 
commonly reported adverse events in this study were nausea, the 
causality assessment was done by using WHO scale and 21 patients 
reported nausea during the treatment. dechallenge was positive in 
21 (25%), in which 14 patients were Possible and 07 patients had 
probable adverse drug reactions according to the WHO scale. 
 
Table 1: Reasons for anxiety disorder observed in the study 
S. No. Reason for anxiety disorder Total no. of patients (n=84) Percentage (%) 
1. Fear of other judgments 4 4.76 
2. Fear of places 1 1.19 
3. Fear of objects 2 2.38 
4. Separation of parents 3 3.57 
5. Separation of caregiver 2 2.38 
6. Academic difficulty 18 21.42 
7. School dropouts 11 13.09 
8. Medical test 4 4.76 
9. Illness 4 4.76 
10. Personal relationship 3 3.57 
11. Job 3 3.57 
12. Socio-economic needs 4 4.76 
13. Substance abuse 10 11.90 
14. Physical abuse 3 3.57 
15. Personality traits 2 2.38 
16. Imaginary creatures 3 3.57 
17. Genetics 3 3.57 
18. Unknown 4 4.76 
 
Table 2: Overall anxiety score in 84 patients using the ham-a scale 
S. No. Conditions Baseline (BT) Week 4 (AT) Week 8 (AT) 
1. Anxious mood 279 171 145 
2. Tension 249 217 136 
3. Fears 266 177 112 
4. Insomnia 248 166 108 
5. Intellectual 245 140 91 
6. Depressed mood 249 200 94 
7. Somatic complaints–muscular 145 145 93 
8. Somatic complaints–sensory 138 128 80 
9. Cardiovascular symptoms 154 144 88 
10. Respiratory symptoms 147 135 94 
11. Gastrointestinal symptoms 176 150 97 
12. Genitourinary symptoms 179 159 112 
13. Autonomic symptoms 186 164 86 
14. Behaviour at interview 205 182 128 
BT-Before treatment AT-After treatment 
 
Table 3: Comparison of anxiety severity at baseline, week 4 and week 8 
S. No. Severity Total no. of patients (n=84) 
Baseline (BT) Week 4 (AT) Week 8 (AT) 
1. Normal 0 3 14 
2. Mild 0 8 34 
3. Moderate 1 23 33 
4. Severe 18 33 3 
5. Very severe 65 17 0 
BT-Before treatment AT-After treatment 
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Statistical inference 
A repeated measure of ANOVA with sphericity determined that 
mean HAM-A score differed statistically significant between time 
points (F (2,166=558.880) = P<0.001). Post hoc tests using the 
Bonferroni correction revealed that paroxetine for anxiety disorder 
elicited a reduction in HAM-A score from baseline to week 4and 
week 8 of paroxetine (34.12±4.75, 27.12±5.43, 17.43±5.31 
respectively) Which was statistically significant (P<0.001). 
Therefore, we conclude that a paroxetine treatment for anxiety 
disorder elicits a statistically significance reduction in HAM-A score 
by week 4 and week 8. 
DISCUSSION 
A prospective observational study was conducted for a duration of 6 
mo. This study includes 84 patients treated with paroxetine for 
various types of anxiety disorder and assessed by HAM-A in the 
outpatient Psychiatry ward. The prevalence of anxiety disorder in 
the study was higher in females (61.90%) than males (38.09%) 
which was similar to the study conducted by M. K. C. Nair et al., in 
which female (63.4%) are higher than male (36.6%) [8]. Among 84 
teenage patients, 52 were female and 32 were male, the prevalence 
of anxiety disorder was higher in female than male. A similar study 
carried out by Angelina et al., out of 91 patients, 54 were female and 
37 were male [1]. This study includes a teenage patient’s age 
between 13 and 19 (21.42% male and 48.80% female). The 
prevalence of patients with anxiety disorder found in age group 
between 14 and 17 were high, this result was concordance with 
study conducted by Borwin Bondelow et al. [9]. Angelina et al., 
conducted a study on anxiety disorder students whose age ranged 
from 9-18 y with a modal age of 13 y, which was similar to this study 
were patient’s age ranged from 13-19 y with a model of 14 y was 
observed [1]. In this study, about 32.14% of generalized anxiety 
disorder and 22.61% Specific phobia was the most onsets in 
teenagers; this is concordant with an epidemiological study carried 
out by Borwin Bondelow et al., social anxiety disorder and specific 
phobia were high onset in this age group [9]. Academic difficulty 
(21.42%) contributes as a reason for most of the anxiety caused in 
teenage patients, this results were similar to the study conducted by 
Angela et al. in school student with an anxiety disorder were poor 
academic performance (34.06%) was the reason for cause [1]. 
Hamilton anxiety rating scale scores were significantly decreased over 
week 8 with paroxetine in this study which correlates with a study 
conducted by Tae–Suk Kim et al., compared 51 paroxetine with 
Venlafaxine extended-release given over 8 w for patients between 18 
and 65 y assessed using HAM-A scale where scores significantly 
decreased over week 8 with paroxetine [10]. Tae–Suk Kim et al., 
assessed the efficacy of paroxetine with the HAM-A and CGI-S scale at the 
baseline, week 1, week 4 and week 8. In this study, paroxetine efficacy 
assessed with HAM-A scale at the baseline, week 4 and week 8 [10]. The 
most commonly reported adverse events in teenagers were nausea, and 
the risk assessment done by using WHO scale, but in Gulseren et al. 
conducted a comparative study on fluoxetine and paroxetine in adults 
with T2DM, adverse events reported were insomnia and anxiety [11]. 
Paroxetine is significantly effective in social anxiety disorder in this study 
and it was concordance with study carried out by Wagner et al. in young 
people and adolescents [12]. Repeated measures of ANOVA showed a 
significant reduction effect on time. 
CONCLUSION  
The study demonstrated that paroxetine is effective and well 
tolerated for the treatment of various types of anxiety disorder in 
teenagers. There was no significant weight gain was observed in 
patient during the study. The clinical applicability of paroxetine 
showed greater promise in treating anxiety in teenagers with fewer 
side effects. 
LIMITATION 
Need to study from large sample size and the drug paroxetine should 
be compared with other SSRIs for better anti-anxiety effect and high 
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